LONDON, July 22 /PRNewswire-FirstCall/ -- GSK announced its sales and turnover fell by less than expected in Q2. The Pharma giant also said there had been good growth in the consumer, vaccine, european and emerging markets businesses and whilst the US remains under pressure from older products going off patent, the rate of decline has slowed down.
Talking about the improving outlook for the second half of the year, Andrew Witty, GSK Chief Executive, said: "As we go into the second half of the year I expect to see those trends continue and, on top of that we will see significant orders being fulfilled, for example, in pandemic vaccine orders. So H1N1 or Swine 'Flu. We'll also see increased volumes of Relenza, our antiviral, being shipped as well as the kick-in of a series of new products."
The full interview and transcript are available now on http://w3.cantos.com/glaxosmithkline.
It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives.
If you would like to contact us, please email firstname.lastname@example.org or phone +44-207-936-1333.
Copyright©2009 PR Newswire.
All rights reserved